Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection

被引:42
|
作者
Meyers, CD
Kashyap, ML
机构
[1] Vet Affairs Hlth Care Syst, Atherosclerosis Res Ctr, Long Beach, CA 90822 USA
[2] Vet Affairs Hlth Care Syst, Gerontol Sect, Long Beach, CA 90822 USA
[3] Univ Calif Irvine, Div Cardiol, Irvine, CA USA
关键词
high-density lipoproteins; apolipoprotein Al; reverse cholesterol transport; atherosclerosis;
D O I
10.1097/01.hco.0000126582.27767.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Despite the best efforts in reduction of low-density lipoprotein cholesterol, most cardiovascular events are not being prevented. Because high-density lipoprotein (HDL) promotes reverse cholesterol transport and other antiatherogenic effects, interventions aimed at raising HDL cholesterol or mimicking its beneficial effects may greatly improve treatment and prevention of cardiovascular disease. This article reviews the antiatherogenic effects of HDL, recent insights into the mechanisms of action of currently available, and emerging HDL-based therapies. Recent findings New insights into the basic science of HDIL function and metabolism (such as the discovery of beta-chain ATIP synthase as a hepatic catabolic HDL receptor) are further characterizing the importance of HDIL in atheroprotection and identifying novel targets of drug development. Nicotinic acid, fibrates, statins, and thiazolidinediones not only increase HDIL cholesterol but also alter HDIL subpopulation size and composition. Furthermore, these drugs promote direct antiatherogenic effects of HDL (antioxidation, anti-inflammation, antithrombotic effects, endothelial stabilization). Emerging HDL-raising therapies (such as cholesteryl ester transfer protein inhibitors and 1,2-dimyristoyl-sn-glycero-phosphocholine) and novel interventions that mimic HDL's beneficial effects (such as apolipoprotein Al-milano. and apolipoprotein Al mimetic peptides) are proving beneficial in animal and human studies. Summary An understanding of the atheroprotective mechanisms of HDL is essential for the rational use of currently available drugs and directed development of new drugs. Increasing total HDL cholesterol may not be as important as increasing the functional properties of HDL. Cardiovascular disease treatment and prevention can be improved by combining current low-density lipoprotein-based strategies with effective HDL-based interventions.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 50 条
  • [22] HIGH-DENSITY LIPOPROTEINS
    WITZTUM, J
    SCHONFELD, G
    DIABETES, 1979, 28 (04) : 326 - 333
  • [23] Endothelial protection by high-density lipoproteins - From bench to bedside
    Calabresi, L
    Gomaraschi, M
    Franceschini, G
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) : 1724 - 1731
  • [24] Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis
    Di Bartolo, Belinda A.
    Schwarz, Nisha
    Andrews, Jordan
    Nicholls, Stephen J.
    ARCHIVES OF MEDICAL SCIENCE, 2017, 13 (01) : 210 - 214
  • [25] Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis
    Marcus E. Kleber
    Tanja B. Grammer
    Ursula Kassner
    Günther Silbernagel
    Winfried März
    Drugs, 2014, 74 : 513 - 520
  • [26] Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis
    Kleber, Marcus E.
    Grammer, Tanja B.
    Kassner, Ursula
    Silbernagel, Guenther
    Maerz, Winfried
    DRUGS, 2014, 74 (05) : 513 - 520
  • [27] Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins
    Swertfeger, Debi K.
    Rebholz, Sandra
    Li, Hailong
    Shah, Amy S.
    Davidson, William Sean
    Lu, Long J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (06) : 1539 - 1548
  • [28] Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available amd emerging therapies
    Meyers, CD
    Kashyap, ML
    CURRENT OPINION IN CARDIOLOGY, 2005, 20 (04) : 307 - 312
  • [29] INTERRELATIONSHIP OF TRIGLYCERIDES WITH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEINS
    GOTTO, AM
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (06): : A20 - A23
  • [30] PROGESTAGENS AND HIGH-DENSITY LIPOPROTEINS
    GODSLAND, IF
    WYNN, V
    LANCET, 1984, 2 (8416): : 1406 - 1406